Autotelicbio

Autotelic Bio Inc. (Korean: 오토텔릭바이오) is a South Korean biotechnology company developing innovative new drugs, with a stated focus on treatments for central nervous system (CNS) disorders and rare, incurable diseases. Its scientific approach centers on antisense oligonucleotide (ASO) therapeutics, which the company describes as inhibiting production of disease-associated target proteins by blocking disease-expressing genes at the mRNA level, positioning the platform as a means of addressing targets considered undruggable by conventional modalities.

The company's pipeline is identified by ATB-series program codes, including ATB-101, ATB-301, ATB-320, ATB-610 and ATB-810. A clinical development registry lists five trials associated with the organization across six trial active ingredients, with a highest development phase of Phase 3; Phase 3 ingredients listed include atb-1013 and dapagliflozin, and Phase 1 ingredients include aldesleukin, atb-320, olmesartan and taso-001. The registry records the first clinical trial in 2021 and no marketed drug or NDA approval to date.

Autotelic Bio is headquartered in Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, with an R&D center in Suji-gu, Yongin-si, Gyeonggi-do. The company states core values of innovation, shared growth and transparency, and describes governance through a board of directors and a steering committee with communication to investors.

Founding story

The company was established in November 2015 as Autotelic Korea and received corporate R&D center accreditation in September 2017. In January 2018 it changed its name from Autotelic Korea to Autotelic Bio, and in February 2018 received venture designation from the Korea Technology Finance Corporation.

Business model

The company develops proprietary drug candidates and monetizes them through out-licensing, technology transfer and co-development arrangements with pharmaceutical partners in specific territories, supplemented by government and public-foundation R&D grants and equity investment from venture and strategic corporate investors.

Revenue arises from licensing and technology transfer agreements with pharmaceutical partners (for example, exclusive license and supply agreements for ATB-101 in Mexico and Brazil) and from co-development agreements, alongside non-dilutive public R&D grant funding.

Traction

A clinical registry records five trials with six trial active ingredients, a highest phase of Phase 3, a first clinical trial in 2021 and no marketed drug or NDA approval; last known activity is recorded as 2025. Company-reported milestones include Phase 1 IND approvals for ATB-101 and ATB-301 (2021), successful completion of an ATB-101 Phase 1 DDI/PK study (2021), Phase 3 IND approval for ATB-101 (2022), multiple government R&D grants, and licensing deals for ATB-101 with Chinoin (Mexico, 2024) and Aché (Brazil, 2025).

Latest developments

In June 2025 Autotelic Bio signed an exclusive license and technology transfer agreement with Aché of Brazil for ATB-101. In January 2026, ATB-810 was selected for the Ministry of SMEs and Startups' Deep Tech Challenge Project.